The proportion of patients experiencing an adverse event was significantly higher in the T2DM group that received insulin than in either the T2DM group that did not receive insulin or the non-DM group (29.5% vs. 15.4% vs. 8.4%; P = 0.004). Here, INS is linked to diabetes mellitus.